| Literature DB >> 33937402 |
Tahmine Salehi1, Naiemeh Seyedfatemi2, Mohammad Saeed Mirzaee2, Maryam Maleki3, Abbas Mardani4.
Abstract
AIM: To describe and synthesize aspects of knowledge, attitudes, and practice regarding pharmacovigilance and adverse drug reaction (ADR) reporting and to explore associated barriers from a nurse perspective.Entities:
Mesh:
Year: 2021 PMID: 33937402 PMCID: PMC8062168 DOI: 10.1155/2021/6630404
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
General characteristics of the included studies.
| Authors, year | Country | Study design/full-text appraisal score | Study setting | Sampling method | Sample size |
|---|---|---|---|---|---|
| Abdel-Latif and Abdel-Wahab [ | Saudi Arabia | A cross-sectional questionnaire-based study/22 out of 32 | 9 hospitals | Random sampling | 158 |
| Abu Hammour et al. [ | Jordan | A cross-sectional questionnaire-based study/24 out of 32 | One hospital | Convenience sampling | 214 |
| Ahmed et al. [ | Pakistan | A cross-sectional questionnaire-based study/17 out of 32 | One hospital | Unclear | 25 |
| Al Rabayah et al. [ | Jordan | A cross-sectional questionnaire-based study/17 out of 32 | One cancer center | Unclear | 154 |
| AlShammari and Almoslem [ | Saudi Arabia | A cross-sectional questionnaire-based study/21 out of 32 | Nine hospitals | Random sampling | 110 |
| Bepari et al. [ | India | A cross-sectional questionnaire-based study/18 out of 32 | One hospital | Convenience sampling | 64 |
| Bogolubova et al. [ | South Africa | A cross-sectional questionnaire-based study/24 out of 32 | Six hospitals | Purposive sampling | 6183 |
| Danekhu et al. [ | Nepal | A descriptive, cross-sectional questionnaire-based study/26 out of 32 | One hospital | Stratified random sampling | 126 |
| Dorji et al. [ | Bhutan | A cross-sectional questionnaire-based study/21 out of 32 | Four hospitals | Census sampling | 257 |
| Ekman et al. [ | Sweden | A cross-sectional questionnaire-based study/25 out of 32 | Nurses who are members of the Swedish Association of Health Professionals | Random sampling | 453 |
| Ergün et al. [ | Turkey | A cross-sectional questionnaire-based study/16 out of 32 | One hospital | Unclear | 321 |
| Ganesan et al. [ | India | A cross-sectional questionnaire-based survey/18 out of 32 | One hospital | Unclear | 171 |
| Gordhon and Padayachee [ | South Africa | A cross-sectional questionnaire-based study/23 out of 32 | One hospital | Stratified sampling | 230 |
| Güner and Ekmekci [ | Turkey | A cross-sectional questionnaire-based study/20 out of 32 | Online survey | Convenience sampling | 67 |
| Hanafi et al. [ | Iran | A cross-sectional questionnaire-based study/22 out of 32 | One hospital | Census sampling | 224 |
| John et al. [ | United Arab Emirates | A cross-sectional questionnaire-based study/25 out of 32 | One hospital and one research center | Census sampling | 91 |
| Rajalakshmi et al. [ | India | A cross-sectional questionnaire-based study/15 out of 32 | One hospital | Unclear | 101 |
| Santosh et al. [ | Nepal | A cross-sectional questionnaire-based study/18 out of 32 | Four hospitals | Unclear | 135 |
| Shamim et al. [ | Pakistan | A cross-sectional questionnaire-based study/21 out of 32 | Five hospitals and an orthopedics and medical institute | Unclear | 69 |
| Shanko and Abdela [ | Ethiopia | A cross-sectional questionnaire-based study/26 out of 32 | One hospital | Purposive sampling | 230 |
| Tandon et al. [ | India | A retrospective observational, prospective cross-sectional study/18 out of 32 | One hospital | Quota sampling | 100 |
| Terblanche et al. [ | South Africa | A cross-sectional questionnaire-based study/21 out of 32 | One hospital | Convenience sampling | 77 |
| Vural et al. [ | Turkey | A cross-sectional questionnaire-based study/20 out of 32 | One hospital | Census sampling | 112 |
The search strategy and results of different phases of the study.
| Databases from 2010 to 2020 | Total in each database | Title selection | Abstract selection | Full-text appraisal |
|---|---|---|---|---|
| MEDLINE | 1702 | 12 | 10 | 7 |
| Scopus | 1529 | 6 | 3 | 1 |
| Embase | 794 | 31 | 14 | 11 |
| Web of Science | 1377 | 8 | 5 | 3 |
| Manual search/backtracking references | 223 | 5 | 1 | 1 |
| Total of databases | 5625 | 62 | 33 | 23 |
Figure 1The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA (available here)).
Nurses' knowledge, attitude, and practice toward pharmacovigilance and ADR reporting.
| Author | Domains | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Knowledge (% yes) | Attitude (% yes) | Practice (% yes) | |||||||||||||
| PV definition | ADR definition | Knowledge of ADR reporting | Awareness of ADR reporting form | Awareness of the national PV system | Receiving training about PV and ADR reporting | ADR reporting important for patient/medicine safety | ADR reporting is a professional commitment | ADR reporting is necessary | ADR reporting should be mandatory | ADR reporting should be voluntary | Fear of legal liability following ADR reporting | Advising patients on possible ADR | History of encountering a patient with ADR | History of ADR reporting | |
| Abdel-Latif and Abdel-Wahab [ | 99.3 | 27.2 | 73.4 | ||||||||||||
| Abu Hammour et al. [ | 36.0 | 79.0 | 50.0 | 89.7 | 74.8 | 34.6 | |||||||||
| Ahmed et al. [ | 60.0 | 28.0 | 72.0 | 72.0 | |||||||||||
| AlShammari and Almoslem [ | 16.0 | 70.0 | 21.0 | ||||||||||||
| Bepari et al. [ | 26.6 | 89.1 | 4.7 | 45.3 | |||||||||||
| Bogolubova et al. [ | 23.6 | 68.0 | 81.4 | 76.6 | 21.5 | ||||||||||
| Danekhu et al. [ | 46.0 | 54.8 | 6.3 | 14.3 | 59.5 | ||||||||||
| Dorji et al. [ | 55.6 | 85.2 | |||||||||||||
| Ekman et al. [ | 14.0 | ||||||||||||||
| Ergün et al. [ | 60.0 | 36.0 | 75.0 | 91.0 | 41.0 | 21.0 | |||||||||
| Ganesan et al. [ | 54.0 | 36.0 | 5.0 | 67.0 | 25.0 | ||||||||||
| Gordhon and Padayachee [ | 46.4 | 88.9 | |||||||||||||
| Güner and Ekmekci [ | 22.4 | 43.3 | |||||||||||||
| Hanafi et al. [ | 32.1 | 34.8 | 20.1 | 37.1 | |||||||||||
| John et al. [ | 83.5 | 49.5 | 87.9 | 82.4 | 8.8 | ||||||||||
| Rajalakshmi et al. [ | 90.0 | 50.5 | 39.6 | 73.2 | 28.7 | ||||||||||
| Santosh et al. [ | 80.0 | 57.8 | 77.8 | 63.0 | 36.3 | ||||||||||
| Shamim et al. [ | 42.0 | 24.6 | 10.1 | 55.1 | 68.1 | 62.3 | 66.7 | ||||||||
| Shanko and Abdela [ | 21.7 | 56.5 | 52.6 | 58.2 | 72.2 | 63.9 | 44.3 | 58.2 | |||||||
| Tandon et al. [ | 4.1 | ||||||||||||||
| Terblanche et al. [ | 1.3 | 78.0 | 83.1 | 6.5 | 8.0 | ||||||||||
| Vural et al. [ | 74.1 | 50.0 | 70.5 | 8.0 | |||||||||||
| Median (IQR) | 34.0 (25.3-49.5) | 74.1 (55.2-81.2) | 50.0 (44.23-82.60) | 26.3 (16.6-54.6) | 31.6 (15.5-50.2) | 38.7 (4.0-73.2) | 84.6 (71.1-89.7) | 71.4 (60.4-77.9) | 66.7 (49.7-75.0) | 76.5 | 72.2 (39.3-81.6) | 37.1 (35.8-43.8) | 53.6 (40.5-71.0) | 67.1 (43.4-75.5) | 21.2 (8.6-41.7) |
ADR: adverse drug reaction; IQR: interquartile range; PV: pharmacovigilance.
Barriers toward ADR reporting by the nurses.
| Author, year | Barriers to ADR reporting (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lack of access to ADR forms | Lack of time | Lack of knowledge/training | Lack of motivation/feedback | Confidentiality/legal problem | Uncertainty in diagnosis | Lack of information provided by patients | Lack of promotion by the authorities | Difficulty in filling the form | Lack of importance | Not my responsibility | Well known ADRs | |
| Abu Hammour et al. [ | 57.0 | 53.0 | 34.6 | 68.2 | 48.1 | 25.2 | ||||||
| Ahmed et al. [ | 36.0 | 52.0 | 36.0 | 20.0 | ||||||||
| Al Rabayah et al. [ | 7.0 | 27.0 | 33.0 | 19.0 | 2.0 | 6.0 | 17.0 | |||||
| Bepari et al. [ | 12.5 | 9.4 | 23.4 | 54.7 | ||||||||
| Danekhu et al. [ | 0.8 | 44.4 | 15.9 | 38.9 | ||||||||
| Ekman et al. [ | 39.0 | 30.0 | 51.0 | 37.0 | 56.0 | |||||||
| Ergün et al. [ | 38.0 | 40.0 | 52.0 | 53.0 | 27.0 | 36.0 | 36.0 | |||||
| Güner and Ekmekci [ | 3.0 | 10.5 | 14.9 | 14.9 | ||||||||
| John et al. [ | 33.0 | 45.1 | 49.5 | 31.9 | ||||||||
| Rajalakshmi et al. [ | 50.4 | 16.8 | 32.6 | 18.8 | ||||||||
| Shamim et al. [ | 59.4 | 55.0 | 49.2 | 26.1 | ||||||||
| Tandon et al. [ | 91.0 | 82.0 | 88.0 | 91.0 | ||||||||
| Median (IQR) | 38.5 (14.7-50.2) | 31.5 (9.0-51.2) | 47.1 (33.7-51.7) | 17.9 | 34.6 (22.0-43.8) | 29.8 (21.2-50.1) | 42.0 | 43.5 | 36.0 | 25.2 (18.8-57.7) | 15.9 | 43.9 |
ADRs: adverse drug reactions.